199 related articles for article (PubMed ID: 20460152)
1. Reduced creatine kinase as a central and peripheral biomarker in Huntington's disease.
Kim J; Amante DJ; Moody JP; Edgerly CK; Bordiuk OL; Smith K; Matson SA; Matson WR; Scherzer CR; Rosas HD; Hersch SM; Ferrante RJ
Biochim Biophys Acta; 2010; 1802(7-8):673-81. PubMed ID: 20460152
[TBL] [Abstract][Full Text] [Related]
2. Impaired brain creatine kinase activity in Huntington's disease.
Zhang SF; Hennessey T; Yang L; Starkova NN; Beal MF; Starkov AA
Neurodegener Dis; 2011; 8(4):194-201. PubMed ID: 21124007
[TBL] [Abstract][Full Text] [Related]
3. Plasma inflammatory biomarkers for Huntington's disease patients and mouse model.
Chang KH; Wu YR; Chen YC; Chen CM
Brain Behav Immun; 2015 Feb; 44():121-7. PubMed ID: 25266150
[TBL] [Abstract][Full Text] [Related]
4. Besides Huntington's disease, does brain-type creatine kinase play a role in other forms of hearing impairment resulting from a common pathological cause?
Lin YS; Wang CH; Chern Y
Aging (Albany NY); 2011 Jun; 3(6):657-62. PubMed ID: 21685512
[TBL] [Abstract][Full Text] [Related]
5. Dysregulated brain creatine kinase is associated with hearing impairment in mouse models of Huntington disease.
Lin YS; Chen CM; Soong BW; Wu YR; Chen HM; Yeh WY; Wu DR; Lin YJ; Poon PW; Cheng ML; Wang CH; Chern Y
J Clin Invest; 2011 Apr; 121(4):1519-23. PubMed ID: 21403395
[TBL] [Abstract][Full Text] [Related]
6. Rho Kinase Pathway Alterations in the Brain and Leukocytes in Huntington's Disease.
Narayanan KL; Chopra V; Rosas HD; Malarick K; Hersch S
Mol Neurobiol; 2016 May; 53(4):2132-40. PubMed ID: 25941073
[TBL] [Abstract][Full Text] [Related]
7. Early defect of transforming growth factor β1 formation in Huntington's disease.
Battaglia G; Cannella M; Riozzi B; Orobello S; Maat-Schieman ML; Aronica E; Busceti CL; Ciarmiello A; Alberti S; Amico E; Sassone J; Sipione S; Bruno V; Frati L; Nicoletti F; Squitieri F
J Cell Mol Med; 2011 Mar; 15(3):555-71. PubMed ID: 20082658
[TBL] [Abstract][Full Text] [Related]
8. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of brain-type creatine kinase activity ameliorates neuronal deficits in Huntington's disease.
Lin YS; Cheng TH; Chang CP; Chen HM; Chern Y
Biochim Biophys Acta; 2013 Jun; 1832(6):742-53. PubMed ID: 23416527
[TBL] [Abstract][Full Text] [Related]
10. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
[TBL] [Abstract][Full Text] [Related]
11. Reduced Expression of Foxp1 as a Contributing Factor in Huntington's Disease.
Louis Sam Titus ASC; Yusuff T; Cassar M; Thomas E; Kretzschmar D; D'Mello SR
J Neurosci; 2017 Jul; 37(27):6575-6587. PubMed ID: 28550168
[TBL] [Abstract][Full Text] [Related]
12. Degeneration of ipRGCs in Mouse Models of Huntington's Disease Disrupts Non-Image-Forming Behaviors Before Motor Impairment.
Lin MS; Liao PY; Chen HM; Chang CP; Chen SK; Chern Y
J Neurosci; 2019 Feb; 39(8):1505-1524. PubMed ID: 30587542
[TBL] [Abstract][Full Text] [Related]
13. Creatine kinase BB isoenzyme blood levels in trauma patients with suspected mild traumatic brain injury.
Carr ME; Masullo LN; Brown JK; Lewis PC
Mil Med; 2009 Jun; 174(6):622-5. PubMed ID: 19585776
[TBL] [Abstract][Full Text] [Related]
14. R6/2 Huntington's disease mice develop early and progressive abnormal brain metabolism and seizures.
Cepeda-Prado E; Popp S; Khan U; Stefanov D; Rodríguez J; Menalled LB; Dow-Edwards D; Small SA; Moreno H
J Neurosci; 2012 May; 32(19):6456-67. PubMed ID: 22573668
[TBL] [Abstract][Full Text] [Related]
15. 20(
Zhu Z; Cheng Y; Han X; Wang T; Zhang H; Yao Q; Chen F; Gu L; Yang D; Chen L; Zhao Y
J Agric Food Chem; 2024 May; 72(18):10376-10390. PubMed ID: 38661058
[TBL] [Abstract][Full Text] [Related]
16. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms.
Hebb AL; Robertson HA; Denovan-Wright EM
Neuroscience; 2004; 123(4):967-81. PubMed ID: 14751289
[TBL] [Abstract][Full Text] [Related]
17. Neuroimaging, Urinary, and Plasma Biomarkers of Treatment Response in Huntington's Disease: Preclinical Evidence with the p75
Simmons DA; Mills BD; Butler Iii RR; Kuan J; McHugh TLM; Akers C; Zhou J; Syriani W; Grouban M; Zeineh M; Longo FM
Neurotherapeutics; 2021 Apr; 18(2):1039-1063. PubMed ID: 33786806
[TBL] [Abstract][Full Text] [Related]
18. Energy dysfunction in Huntington's disease: insights from PGC-1α, AMPK, and CKB.
Ju TC; Lin YS; Chern Y
Cell Mol Life Sci; 2012 Dec; 69(24):4107-20. PubMed ID: 22627493
[TBL] [Abstract][Full Text] [Related]
19. Analysis of YFP(J16)-R6/2 reporter mice and postmortem brains reveals early pathology and increased vulnerability of callosal axons in Huntington's disease.
Gatto RG; Chu Y; Ye AQ; Price SD; Tavassoli E; Buenaventura A; Brady ST; Magin RL; Kordower JH; Morfini GA
Hum Mol Genet; 2015 Sep; 24(18):5285-98. PubMed ID: 26123489
[TBL] [Abstract][Full Text] [Related]
20. Leptin deficiency reverses high metabolic state and weight loss without affecting central pathology in the R6/2 mouse model of Huntington's disease.
Sjögren M; Soylu-Kucharz R; Dandunna U; Stan TL; Cavalera M; Sandelius Å; Zetterberg H; Björkqvist M
Neurobiol Dis; 2019 Dec; 132():104560. PubMed ID: 31419548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
